Search Results - Belger, M

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)

    Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) by Dhainaut, J, Antonelli, M, Wright, P, Belger, M, Cobas-Meyer, M, Mignini, M, Janes, J

    Published 2008
    Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer’s Disease: Transforming Functional Scores into Levels of Dependence

    Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer’s Disease: Transforming Functional Scores into Levels of Dependence by Kahle-Wrobleski, K., Andrews, J.S., Belger, M., Gauthier, S., Stern, Y., Rentz, D.M., Galasko, D.

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer’s Disease: 18-Month Results from the GERAS Observational Study

    Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer’s Disease: 18-Month Results from the GERAS Observational Study by Kahle-Wrobleski, K., Andrews, J.S., Belger, M., Ye, W., Gauthier, S., Rentz, D.M., Galasko, D.

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: